Notably, while these biomarkers predominantly discriminate between TIA or AIS and healthy controls, our identified miRNA panel distinguishes between AIS and TIA patients and benefits more from superior discriminatory performance than candidate biomarkers for stroke, such as C-reactive protein levels (AUC 0.73 [64,65]). Here, CRP is linked to androgen insensitivity syndrome.